CCO headed into mid-August on the front foot, gaining 5% on the week to CAD 137.51, as the broader uranium complex rallied and the stock's own earnings momentum reinforced the bullish narrative — leaving the real question about whether that premium valuation can hold.
The lending market offers no friction for bears. Borrow availability is about as loose as it gets: more than 8,500% of shares-already-shorted remain available to lend, meaning roughly 85 shares sit available for every one currently borrowed. Cost to borrow has dropped sharply — down more than 70% on the week to just 0.47% annually, a near-negligible fee. Short interest itself is a non-story at 0.77% of the free float, slightly higher than a month ago but well within noise. There is no short-side pressure story here. The bears either don't believe in the thesis or can't find enough conviction to pay up, and the data supports that read.
The more interesting angle is what the Street has recently paid for. Valuation has re-rated higher over the past month: the P/E has expanded by more than four points to 62.6x trailing, price-to-book has climbed to 7.2x, and EV/EBITDA holds above 26x. None of those are cheap. The EV/EBIT factor score ranks in just the 2nd percentile — meaning almost every stock in the universe looks cheaper on that measure. Bulls can point to genuinely strong earnings momentum: the 12-month forward EPS growth estimate ranks in the 89th percentile, and 30- and 90-day EPS momentum both score at 70. Analyst data available in the system dates to early 2021 and reflects a far lower share price, so it is omitted here to avoid misleading comparisons. The dividend score ranks in the 98th percentile, though the dividend history in the data is stale and the absolute yield is minimal at current prices.
The most recent earnings print, from July 31, is the clearest fundamental signal. The stock rose 6% the day of the result and added nearly another 4% over the following week — a 10% five-day gain. The prior Q1 result in May ran the other way, down 5% on the day and close to 9% over five days. That swing between outcomes is worth noting: Cameco's quarterly prints can cut either direction depending on realised uranium prices and contract mix. The next event is scheduled for October 30.
Peer performance this week reinforces that the move is sector-wide rather than idiosyncratic. EFR gained 13.7% on the week, ISO added 14.9%, and DML rose 9.3% — all outpacing Cameco's 5% move. NXE also gained 7.1%. Cameco, as the largest and most liquid name in the group, typically absorbs capital more slowly in a sector rally, which is consistent with what the data shows this week. The short score of 27.6 has been essentially flat for a fortnight, confirming that derivatives and lending market participants are not adding incremental short pressure as the stock recovers from its mid-year pullback.
The October 30 earnings date is the next pivot point — how uranium contract realisations track through Q3, and whether the valuation premium can find fresh fundamental support, will define whether this week's rally marks a recovery or a temporary respite.
See the live data behind this article on ORTEX.
Open CCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
